QS Investors’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

QS Investors’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-400	Closed	-$11K	–	1630
2020 Q2	$11K	Hold	400	–	–	﹤0.01%	1538
2020 Q1	$8K	Buy	+400	New	+$7.77K	﹤0.01%	1548
2017 Q3	–	Sell	-1,071	Closed	-$3K	–	1996
2017 Q2	$3K	Hold	1,071	–	–	﹤0.01%	1661
2017 Q1	$4K	Hold	1,071	–	–	﹤0.01%	1690
2016 Q4	$3K	Buy	+1,071	New	+$3.81K	﹤0.01%	1495

Other funds holding DRNA

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

QS Investors's DRNA Position: Q3 2020 in Review

QS Investors sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2020, closing a stake of 400 shares — an estimated $11K sold.

QS Investors first reported a position in DRNA in Q4 2016 and held it in 5 quarters. The position peaked at $11K in Q2 2020. 172 funds tracked by Wall St. Rank hold DRNA as of Q3 2020.

QS Investors reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
QS Investors sold 400 Dicerna Pharmaceuticals, Inc. shares in Q3 2020, an estimated $11K.
QS Investors first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2016 and held it in 5 quarters.
QS Investors's Dicerna Pharmaceuticals, Inc. position peaked at $11K in Q2 2020.
172 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2020.

Based on QS Investors's 13F filing for Q3 2020, filed 12 Nov 2020.